BlackRock, Inc. 13D and 13G filings for Zevra Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BlackRock Inc. BLK |
4,080,420 7.600% |
1,670,131 (+69.29%) |
Filing |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BlackRock Inc. BLK |
2,410,289 5.800% |
1,557,440 (+182.62%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
BlackRock Inc. BLK |
852,849 2.500% |
-1,382,693 (-61.85%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BlackRock Inc. BLK |
2,235,542 6.300% |
2,235,542 (New Position) |
Filing |